8-K current report · filed Aug 6, 2026

Tarsus Pharmaceuticals, Inc. (TARS) 8-K Current Report: August 6, 2026

Item 1.01Item 3.02Item 8.01TARS overview

Short answer

Tarsus Pharmaceuticals, Inc. (TARS) filed an 8-K current report with the SEC on August 6, 2026 reporting Item 1.01 (Entry into a Material Definitive Agreement), Item 3.02 (Unregistered Sales of Equity Securities), Item 8.01 (Other Events). Alkeus acquisition consideration: $270M cash plus $180M Tarsus stock valued at $61.38 per share.

Tarsus Pharmaceuticals, Inc. 8-K event analysis

AI summary of each reported item and its exhibits

Item 1.01 · Entry into a Material Definitive Agreement

  • Alkeus acquisition consideration: $270M cash plus $180M Tarsus stock valued at $61.38 per share
  • Additional payments: up to $350M tied to U.S. regulatory approval and first commercial sale
  • Ongoing seller economics: low-to-mid single-digit percentage royalties on worldwide gildeuretinol sales
  • Closing expected in 2026, subject to conditions including Hart-Scott-Rodino antitrust clearance
  • Stock consideration subject to resale registration rights and a two-month lock-up, with volume limits for certain holders beyond three months

Item 3.02 · Unregistered Sales of Equity Securities

  • Tarsus plans private-placement issuance of upfront and potential contingent stock consideration to Alkeus stockholders
  • Securities offered only to accredited investors under Securities Act Section 4(a)(2) and Regulation D exemptions
  • Transaction may create dilution for existing Tarsus shareholders through stock-based acquisition consideration
  • Contingent stock consideration remains dependent on specified future conditions recognized in the transaction terms

Item 8.01 · Other Events

  • August 6, 2026 press release announces a Merger Agreement, with transaction details in Exhibit 99.1
  • Acquisition outcome remains subject to closing, creating execution and transaction-completion risk
  • Potential investor impacts include strategic benefits, milestone payments, royalty payments, and resale registration timing
  • Forward-looking statements remain subject to SEC-filed risk factors and may differ materially from expectations

Generated from the filing text and exhibits; verify against the original. What 8-K item codes mean

Other Tarsus Pharmaceuticals, Inc. 8-K filings

Get the next TARS 8-K as it lands

Follow TARS for push alerts, or ask the research agent what this filing means.